Your session is about to expire
← Back to Search
Other
Prosetin for Amyotrophic Lateral Sclerosis (PRO-101 Trial)
Phase 1
Waitlist Available
Research Sponsored by ProJenX
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial tests a new drug called prosetin on healthy adults to ensure it is safe and understand how the body processes it.
Eligible Conditions
- Amyotrophic Lateral Sclerosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ProsetinExperimental Treatment1 Intervention
Part A: single-ascending dose; Part B: multiple doses (7 days)
Group II: PlaceboPlacebo Group1 Intervention
Part A: single-ascending dose; Part B: multiple doses (7 days)
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
ProJenXLead Sponsor
Worldwide Clinical TrialsOTHER
63 Previous Clinical Trials
14,738 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger